Results 1 to 10 of about 251,433 (257)

CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on epidermal growth factor receptor mutant non-small cell lung cancer in vitro and in vivo. [PDF]

open access: yesThorac Cancer, 2020
Background CM082 is a novel angiogenesis inhibitor targeting vascular endothelial growth factor receptor (VEGFR) and platelet‐derived growth factor receptor (PDGFR).
Zhang K, Wang L, Wei A, Jia X, Liu X.
europepmc   +2 more sources

Phase 1/2a Study of Rivoceranib, a Selective VEGFR-2 Angiogenesis Inhibitor, in Patients with Advanced Solid Tumors. [PDF]

open access: yesCancer Res Treat
Kang YK   +13 more
europepmc   +1 more source

First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation. [PDF]

open access: yesJ Cancer Res Clin Oncol, 2020
Landre T   +5 more
europepmc   +1 more source

A Systems Pharmacology Approach Uncovers Wogonoside as an Angiogenesis Inhibitor of Triple-Negative Breast Cancer by Targeting Hedgehog Signaling. [PDF]

open access: yesCell Chem Biol, 2019
Huang Y   +11 more
europepmc   +1 more source

HIF-1α represses the expression of the angiogenesis inhibitor thrombospondin-2. [PDF]

open access: yesMatrix Biol, 2018
MacLauchlan SC   +9 more
europepmc   +1 more source

Neoadjuvant Therapy of Cervical Carcinoma with the Angiogenesis Inhibitor Bevacizumab: a Single-Centre Analysis. [PDF]

open access: yesGeburtshilfe Frauenheilkd, 2018
Junker P   +9 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy